Impact of systemic anticancer therapy in pediatric optic pathway glioma on visual function: A systematic review

Pediatric optic pathway glioma (OPG) can seriously decrease visual function in the case of progression. Systemic anticancer therapy (SAT) is considered the treatment of first choice for unresectable OPG. New SAT modalities for the treatment of progressive OPG have been introduced in the last decade,...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Carlien A. M. Bennebroek, Laura. E. Wijninga, Jaqueline Limpens, Antoinette Y. N. Schouten-van Meeteren, Peerooz Saeed
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/53d6349a98f449768cbf4a8f18307d06
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:53d6349a98f449768cbf4a8f18307d06
record_format	dspace
spelling	oai:doaj.org-article:53d6349a98f449768cbf4a8f18307d062021-11-04T06:07:14ZImpact of systemic anticancer therapy in pediatric optic pathway glioma on visual function: A systematic review1932-6203https://doaj.org/article/53d6349a98f449768cbf4a8f18307d062021-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8530362/?tool=EBIhttps://doaj.org/toc/1932-6203Pediatric optic pathway glioma (OPG) can seriously decrease visual function in the case of progression. Systemic anticancer therapy (SAT) is considered the treatment of first choice for unresectable OPG. New SAT modalities for the treatment of progressive OPG have been introduced in the last decade, including VEGF and MAPK pathway inhibition. This systematic review evaluated the effect of SAT on change in visual acuity and visual field in OPG. A systematic review was performed on SAT for OPG (January 1990 to August 2020). MEDLINE and EMBASE (Ovid) were searched for studies reporting on change in visual acuity and visual field after treatment with SAT for OPG. Overall, 11 series, including 358 patients, fulfilled the eligibility criteria. After follow-up of median 3.7 years (range: cessation of SAT– 8.2 years), improvement in binocular VA was found in 0–45% of studies, stability in 18–77% and a decrease in 0–82%. Two studies reported on change in visual field (improvement in 19% and 71% of patients), although either the change was not defined or the testing strategy was lacking. Considerable heterogeneity was present among the included studies, such as variety in the combinations of SAT administered, status of neurofibromatosis type 1, definition regarding change in visual acuity, 1- or 2-eye analysis, diversity in anatomic location, and extent of follow-up, all of which made meta-analysis inappropriate. This systematic review suggests that the impact of SAT in OPG on visual function is still unclear. The wide ranges reported on the efficacy of SAT and the observed heterogeneity highlight the need for prospective studies with uniform definitions of outcome parameters.Carlien A. M. BennebroekLaura. E. WijningaJaqueline LimpensAntoinette Y. N. Schouten-van MeeterenPeerooz SaeedPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 16, Iss 10 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Carlien A. M. Bennebroek Laura. E. Wijninga Jaqueline Limpens Antoinette Y. N. Schouten-van Meeteren Peerooz Saeed Impact of systemic anticancer therapy in pediatric optic pathway glioma on visual function: A systematic review
description	Pediatric optic pathway glioma (OPG) can seriously decrease visual function in the case of progression. Systemic anticancer therapy (SAT) is considered the treatment of first choice for unresectable OPG. New SAT modalities for the treatment of progressive OPG have been introduced in the last decade, including VEGF and MAPK pathway inhibition. This systematic review evaluated the effect of SAT on change in visual acuity and visual field in OPG. A systematic review was performed on SAT for OPG (January 1990 to August 2020). MEDLINE and EMBASE (Ovid) were searched for studies reporting on change in visual acuity and visual field after treatment with SAT for OPG. Overall, 11 series, including 358 patients, fulfilled the eligibility criteria. After follow-up of median 3.7 years (range: cessation of SAT– 8.2 years), improvement in binocular VA was found in 0–45% of studies, stability in 18–77% and a decrease in 0–82%. Two studies reported on change in visual field (improvement in 19% and 71% of patients), although either the change was not defined or the testing strategy was lacking. Considerable heterogeneity was present among the included studies, such as variety in the combinations of SAT administered, status of neurofibromatosis type 1, definition regarding change in visual acuity, 1- or 2-eye analysis, diversity in anatomic location, and extent of follow-up, all of which made meta-analysis inappropriate. This systematic review suggests that the impact of SAT in OPG on visual function is still unclear. The wide ranges reported on the efficacy of SAT and the observed heterogeneity highlight the need for prospective studies with uniform definitions of outcome parameters.
format	article
author	Carlien A. M. Bennebroek Laura. E. Wijninga Jaqueline Limpens Antoinette Y. N. Schouten-van Meeteren Peerooz Saeed
author_facet	Carlien A. M. Bennebroek Laura. E. Wijninga Jaqueline Limpens Antoinette Y. N. Schouten-van Meeteren Peerooz Saeed
author_sort	Carlien A. M. Bennebroek
title	Impact of systemic anticancer therapy in pediatric optic pathway glioma on visual function: A systematic review
title_short	Impact of systemic anticancer therapy in pediatric optic pathway glioma on visual function: A systematic review
title_full	Impact of systemic anticancer therapy in pediatric optic pathway glioma on visual function: A systematic review
title_fullStr	Impact of systemic anticancer therapy in pediatric optic pathway glioma on visual function: A systematic review
title_full_unstemmed	Impact of systemic anticancer therapy in pediatric optic pathway glioma on visual function: A systematic review
title_sort	impact of systemic anticancer therapy in pediatric optic pathway glioma on visual function: a systematic review
publisher	Public Library of Science (PLoS)
publishDate	2021
url	https://doaj.org/article/53d6349a98f449768cbf4a8f18307d06
work_keys_str_mv	AT carlienambennebroek impactofsystemicanticancertherapyinpediatricopticpathwaygliomaonvisualfunctionasystematicreview AT lauraewijninga impactofsystemicanticancertherapyinpediatricopticpathwaygliomaonvisualfunctionasystematicreview AT jaquelinelimpens impactofsystemicanticancertherapyinpediatricopticpathwaygliomaonvisualfunctionasystematicreview AT antoinetteynschoutenvanmeeteren impactofsystemicanticancertherapyinpediatricopticpathwaygliomaonvisualfunctionasystematicreview AT peeroozsaeed impactofsystemicanticancertherapyinpediatricopticpathwaygliomaonvisualfunctionasystematicreview
_version_	1718445149722247168

Impact of systemic anticancer therapy in pediatric optic pathway glioma on visual function: A systematic review

Ejemplares similares